aseline. Mean TFBUT increased from 2.98 to 4.08 sec. (P
< 0.0001) and mean corneal/conjunctival staining decreased from 1.21 to 0.79 units (P
Investigators reported that 70% of subjects experienced an improvement of dry eye symptoms and 53% experienced an improvement in dry eye signs while wearing contact lenses. It was also reported that Lacrisert was longer lasting 93% of the time when compared to rewetting solutions.
"The data in this study show that Lacrisert relieves the signs and symptoms of dry eye in contact lens wearers with a history of dry eye," concluded the ORA investigators. "Patients experienced significant improvements in tear film stability as well as ocular surface damage. Lacrisert may be longer-lasting than other available treatments."
American Ophthalmological Society (AOS)
Marguerite McDonald, M.D., F.A.C.S., will present additional data from the study in a presentation at AOS, "LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert) Reduces the Signs and Symptoms of Dry Eye Syndrome (DES) and Improves Patient Quality of Life" (Marguerite McDonald, Gerard D'Aversa, Henry Perry, John Wittpenn and Eric Donnenfeld for the LAC-07-01 Study Group, Saturday, May 16).
Dr. McDonald reports that patients experienced significant improvements in discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P < 0.0001) after 4 weeks of treatment with Lacrisert. Overall, 57% of subjects experienced an improvement of dry eye symptoms and 54% in clinical signs (including Schirmers Test, conjunctival staining and TFBUT).
"The study shows Lacrisert significantly reduces symptoms and clinical signs of moderate to severe dry eye, which is borne out by my own clinical experience as well," stated Dr. McDonald.
Registry Study Methodology
In the Lacrisert study, at visit 1, patients (nPage: 1 2 3 4 5 Related medicine technology :1
. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study2
. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study3
. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer4
. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series5
. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study6
. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study7
. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD8
. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy9
. Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End10
. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate11
. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers